[go: up one dir, main page]

WO2011010139A1 - Dosage et dispositif de dosage - Google Patents

Dosage et dispositif de dosage Download PDF

Info

Publication number
WO2011010139A1
WO2011010139A1 PCT/GB2010/051185 GB2010051185W WO2011010139A1 WO 2011010139 A1 WO2011010139 A1 WO 2011010139A1 GB 2010051185 W GB2010051185 W GB 2010051185W WO 2011010139 A1 WO2011010139 A1 WO 2011010139A1
Authority
WO
WIPO (PCT)
Prior art keywords
mrsa
sample
broth
chamber
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/051185
Other languages
English (en)
Inventor
Howard Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mast Group Ltd
Original Assignee
Mast Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mast Group Ltd filed Critical Mast Group Ltd
Publication of WO2011010139A1 publication Critical patent/WO2011010139A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045—Culture media therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14—Streptococcus; Staphylococcus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/041—Connecting closures to device or container
    • B01L2300/043—Hinged closures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0654—Lenses; Optical fibres
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L9/00—Supporting devices; Holding devices
    • B01L9/06—Test-tube stands; Test-tube holders

Definitions

  • the present invention relates to assays and assay devices.
  • this invention relates to pathogen detection, and more particularly to the detection of methicillin-resistant Staphylococcus aureus (MRSA).
  • MRSA methicillin-resistant Staphylococcus aureus
  • the present invention relates to the compositions, assays and assay devices for the detection of MRSA in a biological sample.
  • Staphylococcus aureus is a cause of a variety of conditions in humans, including skin infections, pneumonia, meningitis, urinary tract infections and food poisoning. S. aureus is also a major cause of health care associated infection (HCAI)
  • MRSA has become exceedingly prevalent as a pathogen in hospital acquired or nosocomial infection.
  • the majority of nosocomial infections in intensive care units are due to MRSA.
  • MRSA is also a major cause of community aquired infection and a route of carriage into the hospital environment.
  • MRSA represents a significant threat to public health.
  • HA MRSA Hospital acquired (HA) MRSA is typically controlled by monitoring patients and personnel for infection. Contact precautions and/or patient isolation may be appropriate when an infection develops or to prevent infections to individuals particularly at risk. Consequently, in clinical activities the quick and reliable identification of MRSA has become important for the diagnosis and treatment of infected patients as well as for implementation and management of hospital infection control procedures.
  • S. aureus Some of the most common infections caused by S. aureus involve the skin, and they include furuncles or boils, cellulitis, impetigo, and postoperative wound infections at various sites. Some of the more serious infections produced by S.aureus are bacteraemia, pneumonia, osteomyelitis, acute endocarditis, myocarditis, pericarditis, cerebritis, meningitis, scalded skin syndrome, and various abscesses.
  • MRSA methicillin-resistant bacterium senicillin-resistant fungus .
  • S. aureus has a remarkable ability to accumulate additional antibiotic resistant determinants, resulting in the formation of multidrug-resistant strains. This resistance limits therapeutic options for treatment and substantially increases patient morbidity and mortality.
  • MRSA emerged in the 1980s as a major clinical and epidemiologic problem in hospitals. MRSA are resistant to all beta-lactams including penicillins, cephalosporins, carbapenems, and monobactams, which are the most commonly used antibiotics to treat S.
  • MRSA infections can only be treated with more toxic and more costiy antibiotics, which are normally used as the last line of defence. Since MRSA can spread easily from patient to patient via personnel and devices, hospitals over the world are confronted with the problem to control MRSA.
  • Methods to detect and identify MRSA based on the detection of MRSA have been described.
  • One such example relies on the use of Petri dish plating of a sample, the selection of any colonies followed by incubation and a detection step consisting of the use of antibiotic susceptibility and confirmation tests.
  • the method is time consuming, taking several days to identify the presence of MRSA and requires several steps each of which can lead to contamination of the sample and the production of false results.
  • S. aureus is a bacterium, whose natural reservoir is mucous or wet/salty skin areas like the groin, anus or nose (anterior nares). In addition it inhabits wounds. Overall, the nose is the predominant environment for S. aureus. However, S. aureus can cause illnesses ranging from minor skin infections (such as pimples, boils, and cellulitis) and abscesses, to severe diseases such as pneumonia, meningitis, endocarditis, toxic shock syndrome (TSS), septicaemia and Multi Organ Dysfunction Syndrome (MODS).
  • minor skin infections such as pimples, boils, and cellulitis
  • TSS toxic shock syndrome
  • MODS Multi Organ Dysfunction Syndrome
  • MRSA methicillin-susceptible Staphylococcus aureus
  • MRSA MRSA Despite its resistance, MRSA generally remained an uncommon finding even in hospital settings until the 1990's when the MRSA prevalence dramatically increased in hospitals where it is now endemic. Moreover, in the US there are increasing reports of outbreaks of MRSA colonisation and infection through skin contact in locker rooms and gymnasiums, even among healthy
  • MRSA MRSA
  • paediatrics Johnson et al., 2005, J Antimicrob Chemother 56 (3):455-612.
  • the number of deaths in the United Kingdom attributed to MRSA has been estimated by various sources to lie in the area of 3000 per year (Johnson, supra).
  • glycopeptide antibiotics do not penetrate very well into infected tissues (this is a particular concern with infections of the brain and meninges and in endocarditis).
  • glycopeptides must not be used to treat methicillin-sensitive S. aureus as outcomes are inferior.
  • patients infected with MRSA do stay longer in hospital than patients just infected with S. aureus.
  • unrecognised colonisation with MRSA may lead to the distribution of MRSA from one patient to the other by replacing the flora of MRSA-uncolonised patients with MRSA. Colonisation is eased by certain risk factors including e.g. previous antibiotic treatment and diabetes as well as previous stays in hospital.
  • the diagnosis of most skin infections is made by the pattern of symptoms and physical findings but it is not usually possible to know whether the infection is caused by Staphylococcus bacteria of any type or another bacterium.
  • a culture can be grown.
  • a method for detecting MRSA in a sample comprising the following steps:
  • the MRSA detection means may comprise any suitable means known to the skilled person.
  • the detection means comprises visual detection.
  • MRSA in a sample may be identified by using different detectable moieties such as size and/or colour.
  • the detection means comprises a visual marker.
  • the detectable moiety may comprise a pH indicator, a fluorescent dye, a chromogen and/or reducing substrates.
  • the detectable marker comprises a chemical which can be reduced. More preferably, the chemical which can be reduced is resorufin.
  • the method relies on the ability of MRSA growing in the broth and reducing resorufin to release dihydroresorufin which produces a colour change from pink to colourless or colourless with a pink halo top layer.
  • the method may comprise the use of one or more substrates capable of reduction.
  • the indicating means comprises resorufin.
  • the method preferably takes place in a single step comprising the contacting of the sample with a broth.
  • there are fewer steps than those associated with the prior art there is less chance for contamination of the sample and/or broth and therefore less chance of an inaccurate result.
  • less skilled technicians are required to carry out the method and less training is required for skilled persons to use the method. Similarily, as there are fewer steps there is an increased likelihood of successful growth of the MRSA organism.
  • the method of the present invention is simpler, faster, more cost effective and more accurate than the prior art methods.
  • the broth may comprise any nutrients necessary to enable any MRSA present to be successfully cultured.
  • the broth may comprise a non-MRSA inhibitor to prevent any other
  • microorganisms present from growing in the culture.
  • the inhibitor comprises any one or more of the following
  • the incubation conditions preferably comprise a temperature range of 35- 37°C for a period of 18 to 24hours
  • Incubation is preferably carried out in a microbiological incubator
  • the broth preferably comprises any one or more of the following constituents: nutrients, one or more non-staphylococci growth inhibitor, sugars, MRSA specific marker and/or one or more antibiotic.
  • the method of the present invention is carried out in a liquid broth.
  • a typical broth will comprise any one or more of the following
  • Nitrogen source 10-20g/l
  • Carbon source 2-10g/l
  • Antibiotic cocktail 50-100mg/l
  • Resorufin 5-15mg/l
  • the nitrogen source comprises peptone and beef extract.
  • the carbon source comprises, pyruvate and/or uracil.
  • the salt component comprises lithium chloride and/or sodium chloride.
  • the buffer comprises Tris-HCI and/or Trizma base.
  • the antibiotics comprises any one or more of cefoxitin, aztreonam, cefmetazole and colistin sulphate
  • the broth comprises:
  • Nitrogen source peptone and beef extract
  • Carbon source pyruvate and uracil
  • Antibiotic cocktail aztreonam, cefmetazole and colistin sulphate
  • Peptones, beef extract, pyruvate and uracil provide the essential nutrients for cultivation of micro-organisms in the liquid medium.
  • Salts typically sodium chloride and lithium chloride inhibit the growth of most bacteria with the exception of staphylococci.
  • Buffers such as Tris HCI and Trizma base provide stabilisation of the liquid media.
  • Cefmetazole is a second generation cephalosporin; MRSA are resistant to cefmetazole whereas MSSA are not.
  • - Aztreonam This is a beta lactam antibiotic, which is active against gram negative bacteria including Pseudomonas aeruginosa. It has no activity against gram positive bacteria.
  • Cefoxitin This is a second-generation cephalosporin; MRSA are resistant to cefoxitin whereas MSSA are not. Cefoxitin is used to differentiate between MSSA and MRSA in the broth.
  • the sample may be obtained by any suitable means known to the skilled person.
  • the sample may be obtained using a swab which is taken from the surface of a subject's skin, for example from the nasal cavity, mouth, arm pit, groin or other suitable location.
  • the biological sample preferably is derived from the anterior nares (nose).
  • the broth is supplied in a selectively sealed vessel which is capable of receiving the sample and which is subsequently re-sealable to prevent contamination.
  • a sample Once a sample has been contacted with the broth, the vessel is sealed and the broth and sample incubated for a pre-determined period of time.
  • the sample and broth is incubated for 18 to 24 hours at a temperature of 35-37°C.
  • the presence of MRSA can preferably be determined by a visual inspection of the incubated broth and sample, thus reducing testing time and shortening the turn-around time for conducting the test and obtaining a result.
  • the required skill for carrying out the test is thus diminished further reducing the associated cost for carrying out the test.
  • the method is automated.
  • a culture broth for use in an MRSA detection method comprising buffer, nutrients, non-MRSA inhibitor and a visible marker for detecting the presence of MRSA.
  • a device for fluid assay comprising a sealable chamber/cavity having an inlet port for allowing a sample to enter the chamber/cavity said inlet port being closable to seal/close the chamber/cavity, said device having a first chamber for receiving a sample and a second chamber in fluid communication with the first such that a fluid can move therebetween, and a second chamber at least a part of the housing defining said chamber has a reading window/ allows passage of light therethrough.
  • kit of parts comprising a re-sealable vessel containing a broth as described hereinabove.
  • the kit of parts may also comprise a colour chart indicating the appropriate colour when MRSA is detected in a sample that has been cultured in the broth.
  • the kit may additionally comprise a swab for obtaining a sample from a subject.
  • the swab is preferably provided in a hermetically sealed sterile packaging to ensure that it is not contaminated prior to obtaining a sample from a subject.
  • One embodiment of the invention provides an instrument comprising a microprocessor operable via a keypad, one or more light emitting diodes (LED's) and one or more associated photodiodes, a display and driver, an analogue to digital converter, and a power source.
  • the optical chamber of the device incorporates a micro-cuvette and the instrument comprises means for measuring the absorbance of the contents of each micro-cuvette.
  • the instrument comprises a LED light source to generate electromagnetic radiation at one side of the sample and an associated photodiode (PD) for measuring the intensity of transmitted light generated across the sample i.e. the instrument measured absorbency.
  • PD photodiode
  • the instrument comprises one or more LED/PD pairs.
  • one or more LED/PD pairs are arranged such that when the instrument is connected to the apparatus one or more LED/PD pairs are disposed across each optical chamber of the device.
  • the apparatus and instrument are connected such that one or more LED/PD pairs are positioned such that a reading can be taken of a sample in the device's optical chamber and then the same one or more LED/PD pairs can be moved to read the sample in the second optical chamber.
  • the optical chambers can be moved relative to the one or more LED/PD pairs.
  • an apparatus comprising a device and an instrument of the invention.
  • the optical chambers preferably have a geometry such that the LED's in the instrument can be positioned such that all rays in the horizontal and / or vertical plane will be perpendicular to the walls of the optical chamber and should not be subjected to refraction. This relaxes rotational location tolerances of the device.
  • the optical surfaces of the optical chambers will be recessed to avoid damage on location in the rack and prevent a risk of them picking up dirt on handling.
  • top and base portions are connected in a manner such that any reagents, such as a broth, are sealed therein. This is most conveniently achieved using a seal between the portions.
  • the base unit is made of a clear material, although depending on the application of the apparatus a tinted or coloured material, preferably plastics could be used.
  • an optical filter can be positioned in front of the optical chamber and a white light source used.
  • the optical filter is preferably a wavelength filter.
  • the device is intended to be disposable.
  • the instrument is run from an external source, for example, a mains source via a transformer. Consequently, the instrument may be provided with a power management and monitoring circuit Preferably the instrument is provided with a communication system thereby providing means for sending and receiving instructions and down loading data.
  • the instrument's electronics may be housed in a case which is specifically adapted for use with the apparatus of the invention. It may comprise a recess into which the device of the invention and/or a rack containing a plurality of devices may sit. The optical chambers of the device may be aligned with the light emitter/light detector arrangement of the instrument.
  • the light emitter/light detector arrangement for example, a mains source via a transformer. Consequently, the instrument may be provided with a power management and monitoring circuit Preferably the instrument is provided with a communication system thereby providing means for sending and receiving instructions and down loading data.
  • the instrument's electronics may be housed in a case which is specifically adapted for use with the apparatus of the invention. It may comprise a recess into which
  • emitter/light detector arrangement preferably comprises a LED/PD
  • a kit comprising an apparatus according to the invention and optionally one or more sample collectors or one step assay devices or reagents and/or a capillary tube and/or an inoculating loop.
  • a point of care method for the detection of an analyte in sample which comprises: (i) separation of the analyte from the sample by the use of chemical or biological means; and (ii) detection/quantifying the analyte by means of an
  • chemical means the use of one or more reagents whose interaction with the analyte is primarily chemical and not biological.
  • a boronate based separation step can be used to separate glycated proteins from non-glycated proteins in a sample.
  • step (i) is achieved using apparatus according to the present invention and step (ii) is achieved by means of a one-step assay device.
  • the optical chamber house a micro cuvettes.
  • the apparatus is adapted to be connected to an instrument with means for measuring the absorbance of the liquid collected in the optical chambers.
  • the instrument may comprise a body housing a micro processor.
  • Instructions can be transmitted to the micro processor via a key pad and information/instructions presented via a liquid crystal display powered by a LDC driver.
  • the micro processor controls one or more LED's which pass light of a given wave length across the optical chamber such that absorbed light is measured by photodiodes.
  • the readings are communicated to the liquid crystal display via an analogue digital converter.
  • a micro switch determines that the device (apparatus and instrument) is activated by the correct connection of the apparatus to the instrument.
  • a LED/phototransistor pair is provided to determine when the apparatus has been disconnected from the instrument.
  • Fig. 1 shows a device in accordance with the present invention
  • Figs. 2a and b show a device in accordance with the present invention and a sectional view along the axis A - A;
  • Fig. 3 is a device mounted on a carrier in accordance with the present invention.
  • Figs. 4a and 4b show the results of a positive and negative assay in accordance with the present invention.
  • Chamber 14 is composed of a number of discrete chambers, one 20 for receiving a sample collection device and the second 22 having a window to aid analysis.
  • the sample collection means (not shown) consists of an absorbent swab mounted on a handle, the swab being absorbent and capable of collecting a biological sample from a subject and the handle having a shaft that is capable of being detached from the swab.
  • the handle may comprise a snap-off point to enable the handle to be removed once a sample has been collected and received by the sample receiving chamber of the device 10.
  • the device 10 contains assay reagents contained within chamber 14 to enable an assay to be performed. Typically, the assay reagents will be in fluid form.
  • the device is most conveniently manufactured in two parts: the lid section and the chamber section.
  • the lid 18 selectively closes the opening 16 to the chamber 14.
  • the lid 18 is hingedly mounted on the inlet port 30 and can be pivotally moved to close the opening by means of a seal between the lid and the inlet port thus forming a substantially hermetic seal.
  • the lid has a cylindrical stopper 32 which is received by the complementarily shaped inlet port 30. An interference fit between the two forms a substantially hermetical seal to prevent the contents of the device from escaping and contaminants entering the chamber which could affect the result of any analysis carried out on a sample located therein.
  • a divider that allows the liquid to circulate between the two chambers but prevents the sample collection device from entering the second chamber 22 and potentially obscuring the reading window disposed therein.
  • the biological sample is collected from a subject, for example a mouth swab, and the swab is received by the deviceiO.
  • the handle of the swab stick is snapped-off and the device 10 sealed by closing the hinged lid.
  • the sample and reagent are then incubated for a period of time and the analysis can then take place.
  • the window of the device may allow a technician to visually determine the outcome of the assay or an automated system may be used, such as a spectrophotometer.
  • a plurality of devices may be used in an automated system.
  • a plurality of devices 10 may be used in conjunction with a carrier or rack (Fig. 3) which is capable of receiving a plurality of devices and securely retaining the devices whilst still enabling the window to accessed by a suitable reading or measuring device such as a spectrophotometer.
  • the rack 50 comprises an elongate frame 52 having a plurality of device receiving members 54 disposed either side along its longitudinal axis. Each receiving member has a recess 56 complementarily shaped to that of the device housing 12 for receiving and retaining the device 10. There is a cut-out 58 at the base of each receiving member corresponding to and adjacent to the position of the window of the device 10 when mounted in the rack to enable a reading device to take a measurement of the sample contained in the device.
  • a protocol for operation of the device is as follows: (i) A sample is collected from the oral cavity, nose, groin, axilla or other body part of a subject using a sample collection device which consists of an absorbent pad mounted on a handle which has a weakened section allowing the absorbent pad to be easily snapped off allowing it to drop into the incubation chamber of the collection device. The absorbent pad is inserted into the device containing broth as described herein and the shaft of the handle snapped to enable the lid to be closed whilst containing the sample disposed on the absorbent pad.
  • the device is inverted several times, which washes the sample out of the absorbent pad and into the broth, (ii) The device is incubated with sample and broth for between 12 and 36 hours at 35-37 degrees Celsius, (iii) During this time, the device which is designed to be disposable, is coupled to the instrument and/or mounted in the rack, (iv) After incubation, the contents of the device will be evenly distributed throughout the container and some will reside in an optical chamber in the base of the device, (v) The instrument then spectrophotometrically measures the absorbance of the contents of the device. The path of light from the instrument is not blocked by the sample collection device as it is located in a discrete section of the chamber having a divider to prevent the collection device from obscuring the optica! window, (vi) The device is disconnected from the instrument and is discarded as biohazardous waste. The instrument is then ready to perform the next test.
  • the spectrophotometric measurement of the sample occurs at the interface of the optical chambers of the apparatus with the instrument of the device.
  • the device In use the device is inserted into the recess of the rack.
  • the apparatus and instrument of the invention can be adapted for use in a number of assays.
  • the instrument can be modified to read any suitable wavelengths.
  • suitable wavelengths for example coloured light, red, green, yellow etc. LED's or white light and the use of optical fibres more preferably wavelength filters could be employed.
  • the apparatus could be modified to make multiple measurement rather single readings.
  • the type of assays might, for example, include: 1. ELISA type assays; 2.
  • Affinity chromatography assays and/or 3. Chemical analysis of analytes.
  • MRSA Methicillin Resistant Staphylococcus aureus
  • MRSA-IDR MASTASCREENTM MRSA PLUS
  • MRSA-ID The known assay, MRSA-ID, has undergone several re-developments and whilst the latest MRSA-ID 1 called MASTASCREENTM MRSA PLUS (MRSA- IDR), has improved performance in comparison to earlier versions improvements in specificity and speed are clearly beneficial.
  • GDS Enterococcus species
  • Broths were labelled with a number representing an organism from 1 to 40.
  • a McFarland 0.5 suspension was prepared for Non-MRSA strains whilst MRSA strains were prepared using a McFarland 0.5 suspension further diluted 10 ⁇ 3 . 5 100 ⁇ l of the appropriate preparation was added to the appropriate broth and mixed.
  • Figs.4a and 4b show the results of a test in accordance with the present invention.
  • Fig. 4a shows that the tube on the left, 200, contains a colourless broth and is therefore positive for MRSA whilst the tube on the right, 202, contains a pink broth and is therefore negative for MRSA.
  • Fig. 4b shows the results of a test carried out in accordance with the present invention using the device of the present invention.
  • Fig. 4b shows that the device on the left, 204, contains a pink broth and is therefore negative for MRSA whilst the tube on the right, 206, contains a colourless broth and is therefore positive for MRSA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte d'une manière générale sur des procédés de détection d'un pathogène. En particulier, la présente invention porte sur de procédés de détection de SARM dans un échantillon biologique.
PCT/GB2010/051185 2009-07-20 2010-07-20 Dosage et dispositif de dosage Ceased WO2011010139A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0912551A GB0912551D0 (en) 2009-07-20 2009-07-20 Assay and assay device
GB0912551.9 2009-07-20

Publications (1)

Publication Number Publication Date
WO2011010139A1 true WO2011010139A1 (fr) 2011-01-27

Family

ID=41058202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/051185 Ceased WO2011010139A1 (fr) 2009-07-20 2010-07-20 Dosage et dispositif de dosage

Country Status (2)

Country Link
GB (1) GB0912551D0 (fr)
WO (1) WO2011010139A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02211899A (ja) * 1989-02-10 1990-08-23 Terumo Corp 細菌の薬剤感受性測定方法
WO1997003209A1 (fr) * 1995-07-12 1997-01-30 Charm Sciences, Inc. Testeur, systeme et procede pour la detection d'echantillons a tester
WO2005049207A1 (fr) * 2003-11-19 2005-06-02 Michael O'donovan Cuve a reactifs
WO2007096639A2 (fr) * 2006-02-24 2007-08-30 Newcastle Upon Tyne Hospitals Nhs Milieu de culture sélectif
WO2009076347A1 (fr) * 2007-12-11 2009-06-18 Siemens Healthcare Diagnostics Inc. Dispositif et procédé pour traiter un échantillon contenu sur un écouvillon pour une analyse diagnostique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02211899A (ja) * 1989-02-10 1990-08-23 Terumo Corp 細菌の薬剤感受性測定方法
WO1997003209A1 (fr) * 1995-07-12 1997-01-30 Charm Sciences, Inc. Testeur, systeme et procede pour la detection d'echantillons a tester
WO2005049207A1 (fr) * 2003-11-19 2005-06-02 Michael O'donovan Cuve a reactifs
WO2007096639A2 (fr) * 2006-02-24 2007-08-30 Newcastle Upon Tyne Hospitals Nhs Milieu de culture sélectif
WO2009076347A1 (fr) * 2007-12-11 2009-06-18 Siemens Healthcare Diagnostics Inc. Dispositif et procédé pour traiter un échantillon contenu sur un écouvillon pour une analyse diagnostique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOHNSON ET AL., J ANTIMICROB CHEMOTHER, vol. 56, no. 3, 2005, pages 455 - 62
PERRY JOHN D ET AL: "Development and evaluation of a chromogenic agar medium for methicillin-resistant Staphylococcus aureus", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US LNKD- DOI:10.1128/JCM.42.10.4519-4523.2004, vol. 42, no. 10, 1 October 2004 (2004-10-01), pages 4519 - 4523, XP002439826, ISSN: 0095-1137 *
SARKER ET AL: "Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US LNKD- DOI:10.1016/J.YMETH.2007.01.006, vol. 42, no. 4, 6 June 2007 (2007-06-06), pages 321 - 324, XP022103481, ISSN: 1046-2023 *
SMITH C F ET AL: "A new medium for determining the total plate count in food.", JOURNAL OF FOOD PROTECTION DEC 1999 LNKD- PUBMED:10606144, vol. 62, no. 12, December 1999 (1999-12-01), pages 1404 - 1410, XP008125791, ISSN: 0362-028X *
TALBOT JANET D ET AL: "Rapid, stimulation-induced reduction of C12-resorufin in motor nerve terminals: linkage to mitochondrial metabolism.", JOURNAL OF NEUROCHEMISTRY MAY 2008 LNKD- PUBMED:18205748, vol. 105, no. 3, May 2008 (2008-05-01), pages 807 - 819, XP000812573, ISSN: 1471-4159 *
WERTHEIM H ET AL: "Improved detection of methicillin-resistant Staphylococcus aureus using phenyl mannitol broth containing aztreonam and ceftizoxime", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US LNKD- DOI:10.1128/JCM.39.7.2660-2662.2001, vol. 39, no. 7, 1 July 2001 (2001-07-01), pages 2660 - 2662, XP002281097, ISSN: 0095-1137 *

Also Published As

Publication number Publication date
GB0912551D0 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
Puttaswamy et al. A comprehensive review of the present and future antibiotic susceptibility testing (AST) systems
US12221646B2 (en) Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics
US8828680B2 (en) Combined rapid susceptibility assay and microorganism identification system
EP0589634B1 (fr) Détection améliorée des micro-organismes
Rahkonen et al. True bacteremias caused by coagulase negative Staphylococcus are difficult to distinguish from blood culture contaminants
CN102131914A (zh) 用于对血浆进行细菌学测试的装置和方法
Liu et al. Parallel validation of the NG-Test Carba 5 and the Xpert Carba-R for detection and characterization of carbapenem-resistant Enterobacterales causing bloodstream infections
Johnson et al. Direct antimicrobial susceptibility testing for acute urinary tract infections in women
AMIN et al. Antimicrobial susceptibility profile of various bacteria isolated from respiratory tract infection
EP1791971A4 (fr) Dispositif et procede de detection d'enzymes inactivant des antibiotiques
US20160349178A1 (en) Antimicrobial Resistance Status Determination Device and Method
US20100120073A1 (en) Methods and devices for detecting organisms causing urinary tract infections
US20040029205A1 (en) Diagnostic system for differentiating sputum from saliva
Sawyer et al. Evaluation of a leukocyte dip-stick test used for screening urine cultures
WO2011010139A1 (fr) Dosage et dispositif de dosage
RU2245922C2 (ru) Способ выявления госпитальных штаммов
JP2011505575A (ja) マクロライド−リンコサミド−ストレプトグラミンｂに対する誘導型耐性の検出
Cutler et al. Evaluation of a radiometric method for studying bacterial activity in the presence of antimicrobial agents
US20100028938A1 (en) Method of screeing for pathogens
WO2017013673A1 (fr) Invention liée à un appareil d'analyse microbiologique
Najem et al. Detection of bacterial species causing urinary tract infections in various parts of Libya's Brega city region, isolation, identification, and antibiotic sensitivity testing.
Alsdig Isolation, identification, and antibiotic sensitivity testing of bacterial species causing urinary tract infection in different zones of Libya's Brega city region
Pfaller et al. Improved urine screening using a combination of leukocyte esterase and the Lumac system
Pfaller et al. Evaluation of laboratory methods for the classification of oxacillin-resistant and oxacillin-susceptible Staphylococcus aureus
US20240271077A1 (en) An automated system for microbial testing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734811

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10734811

Country of ref document: EP

Kind code of ref document: A1